publication . Article . 2020

The Neurobiology of Treatment-Resistant Schizophrenia: Paths to Antipsychotic Resistance and A Roadmap for Future Research

Steven G. Potkin; John M. Kane; Christoph U. Correll; Jean-Pierre Lindenmayer; Ofer Agid; Stephen R. Marder; Mark Olfson; Oliver D. Howes;
Open Access
  • Published: 07 Jan 2020 Journal: FOCUS, volume 18, pages 456-465 (issn: 1541-4094, eissn: 1541-4108, Copyright policy)
  • Publisher: American Psychiatric Association Publishing
AbstractTreatment-resistant schizophrenia (TRS), the persistence of positive symptoms despite ≥2 trials of adequate dose and duration of antipsychotic medication with documented adherence, is a serious clinical problem with heterogeneous presentations. TRS can vary in its onset (at the first episode of psychosis or upon relapse), in its severity, and in the response to subsequent therapeutic interventions (i.e., clozapine, electroconvulsive therapy). The heterogeneity of TRS indicates that the underlying neurobiology of TRS may differ not only from treatment-responsive schizophrenia but also among patients with TRS. Several hypotheses have been proposed for the ...
Medical Subject Headings: hormones, hormone substitutes, and hormone antagonistsendocrine systemanimal structures
free text keywords: Medicine, business.industry, business, Treatment resistant schizophrenia, Antipsychotic, medicine.medical_treatment, Psychiatry, medicine.medical_specialty, Schizophrenia, medicine.disease, Neuroscience, Clinical trial, Clinical research, Electroconvulsive therapy, Psychosis, Clozapine, medicine.drug, First episode
Any information missing or wrong?Report an Issue